Abstract

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) seeks to reduce cancer incidence, mortality, and morbidity in its Northern California catchment area, nationally, and globally. The principles of precision cancer medicine and precision population health systematically and intimately link research and clinical service delivery for patient and population benefit. The HDFCCC builds on the richness of the basic biological insights and the extensive and exceptional clinical research and facilities at UCSF, one of the world's leading health research universities. Moreover, its location in the San Francisco Bay Area allows the HDFCCC to take advantage of one of the most culturally diverse populations and highly innovative and intellectually vibrant environments in the world. This is accomplished through the ten Research Programs supported by seven Shared Resources and clinical and administrative infrastructure.

Public Health Relevance

Director's Overview: Project Narrative The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) seeks to reduce cancer incidence, mortality, and morbidity in its Northern California catchment area, nationally, and globally. The principles of precision cancer medicine and precision population health systematically and intimately link research and clinical service delivery for patient and population benefit.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-19
Application #
9570972
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1999-08-05
Project End
2023-05-31
Budget Start
2018-08-31
Budget End
2019-05-31
Support Year
19
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118

  Publications

Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28

Showing the most recent 10 out of 192 publications